» Articles » PMID: 23856293

Identification of Sirtuin 3, a Mitochondrial Protein Deacetylase, As a New Contributor to Tamoxifen Resistance in Breast Cancer Cells

Overview
Date 2013 Jul 17
PMID 23856293
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The current study reports a previously unappreciated role of Sirtuin 3 (SIRT3), a mitochondrial protein deacetylase, in altering sensitivity of breast cancer cells to tamoxifen (Tam), a commonly used anti-estrogen agent. We showed that SIRT3 was significantly up-regulated at both mRNA and protein levels in the Tam-resistance human breast cancer cell line MTR-3, which was derived from MCF-7 line by continuous selective culture in the presence of 1μM of Tam for two years. We further demonstrated that SIRT3 was rapidly up-regulated in the sensitive MCF-7 cells following exposure to Tam. Transfection of MCF-7 cells with a SIRT3 expression plasmid decreased cellular sensitivity to Tam and blocked the Tam-induced apoptosis. Furthermore, silencing of SIRT3 expression in MTR-3 cells sensitized the resistant cells to Tam and enhanced apoptotic cell death. MTR-3 cells with silencing of SIRT3 expression showed increases in the mitochondrial content of ERβ, ROS level and apoptosis. These results not only uncovered a new role for SIRT3 in cancer but also identified this mitochondrial protein deacetylase as a previously unrecognized factor that participates in regulation of Tam sensitivity in breast cancer cells. Thus, SIRT3 might be considered as a potential target for overcoming Tam resistance in treatment of breast cancer.

Citing Articles

The role of mitochondrial/metabolic axis in development of tamoxifen resistance in breast cancer.

Azzam H, El-Derany M, Wahdan S, Faheim R, Helal G, El-Demerdash E Hum Cell. 2023; 36(6):1877-1886.

PMID: 37646973 PMC: 10587280. DOI: 10.1007/s13577-023-00977-5.


The Double-Edged Sword of SIRT3 in Cancer and Its Therapeutic Applications.

Ouyang S, Zhang Q, Lou L, Zhu K, Li Z, Liu P Front Pharmacol. 2022; 13:871560.

PMID: 35571098 PMC: 9092499. DOI: 10.3389/fphar.2022.871560.


Ultrasound‑targeted microbubble destruction‑mediated overexpression of Sirtuin 3 inhibits the progression of ovarian cancer.

Cheng L, Zhang D, Yan W Oncol Rep. 2021; 46(4).

PMID: 34396428 PMC: 8377464. DOI: 10.3892/or.2021.8171.


Multi-omics approaches identify and as candidate autophagic regulators and druggable targets in invasive breast carcinoma.

Zhang S, Zhang J, An Y, Zeng X, Qin Z, Zhao Y Acta Pharm Sin B. 2021; 11(5):1227-1245.

PMID: 34094830 PMC: 8148052. DOI: 10.1016/j.apsb.2020.12.013.


Genetic Manipulation of Sirtuin 3 Causes Alterations of Key Metabolic Regulators in Melanoma.

Singh C, George J, Chhabra G, Nihal M, Chang H, Ahmad N Front Oncol. 2021; 11:676077.

PMID: 33937086 PMC: 8085490. DOI: 10.3389/fonc.2021.676077.